Dr. Stephen Archer appointed Director, Translational Institute of Medicine (TIME)
On the recommendation of Dean Jane Philpott, Teri Shearer, Interim Provost and Vice-Principal (Academic) has appointed Dr. Stephen Archer as Director, Translational Institute of Medicine (TIME), effective July 1, 2023 until June 30, 2028.
Dr. Archer succeeds Dr. Stephen Vanner in this role. Dr. Philpott extends her sincere gratitude to Dr. Vanner for his leadership in establishing TIME as one of the foremost interdisciplinary institutes at the university that has advanced translational research to accelerate healthcare.
Prior to this appointment, Dr. Archer was head of the Department of Medicine for 10 years during which time he led important changes to curriculum, developed a new strategic plan, implemented EDIIA (Equity, Diversity, Inclusion, Indigeneity, and Accessibility) initiatives, and navigated the challenges posed by the COVID-19 pandemic. Dr. Archer is a widely respected clinical cardiologist, specializing in pulmonary hypertension. He is the founder and scientific director of the Queen’s Cardiopulmonary Unit (QCPU), a translational research facility seeking cures for heart, lung, blood, and vascular diseases; and, along with Dr. Vanner, is a co-founder of TIME.
Dr. Archer is a prolific, highly regarded researcher who holds the C. Franklin and Helene K. Bracken Chair in the School of Medicine. He is a Fellow of the Royal Society of Canada, elected for his work on mitochondrial biology and experimental therapeutics for cardiovascular diseases and cancer. He received the Distinguished Scientist Award from the American Heart Association and American College of Cardiology. He is cross-appointed to the Department of Biomedical and Molecular Sciences and has mentored more than 70 trainees, many of whom are leaders in science and medicine.
As TIME’s Director, Dr. Archer will provide leadership to its 250 clinicians, scientists, researchers, and faculty to ensure the institute’s success in building a cohesive, translational research community at Queen’s to accelerate the discovery of new and effective therapies that improve patient care and outcomes. Dr. Archer will pursue funding opportunities for TIME and ensure its financial vitality along with its graduate program (TMED). He will also lead efforts to celebrate and promote the work of TIME members and help grow its capabilities while supporting the cultivation of world-class science and discoveries.
Please join Dean Philpott in congratulating Dr. Archer on his appointment.